BioNTech SE

General information
BioNTech SE
An der Goldgrube 12
55131 Mainz, Rhineland-Palatinate
Germany

Contact person: Douglas Maffei, Investors@biontech.de
Company main phone: +49 (6131) 90840
Company main fax:  +49 (6131) 90842121
Website:  https://biontech.de
Year founded:2008
Source of foundation:Spin-off from university
Name of foundation source:Johannes Gutenberg University Mainz
No. of employees: Worldwide:  6772
Corporate description / mission:
Biopharmaceutical New Technologies (BioNTech) is a global next generation immunotherapy company pioneering novel investigative therapies for cancer and other serious diseases. BioNTech exploits a wide array of computational discovery and therapeutic modalities with the intent of rapid development of novel biopharmaceuticals. Its diversified portfolio of oncology product candidates aiming to address the full continuum of cancer includes mRNA cancer immunotherapies, next-generation immunomodulators and targeted therapies such as antibody-drug conjugates (ADCs) and innovative chimeric antigen receptor (CAR) T cell therapies. Based on its deep expertise in mRNA development and in-house manufacturing capabilities, BioNTech and its collaborators are researching and developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline
State of ownership: Publicly listed on stock exchange
Headquarters: HQ: Yes
IPO (year): 2019
Categorization
Sector:
  • Biotechnology - Therapeutics and Diagnostics
Subsector:
  • Anti-infectives
  • Antibodies
  • Antibody-drug-conjugate
  • Cell therapy
  • Immunotherapy
  • Nucleic acid drugs
  • Small molecules
  • Vaccines
Primary therapeutic areas:
  • Infectious and parasitic diseases / infectiology / parasitology
  • Neoplasms / cancer / oncology
  • Respiratory / pulmonology
Business model:
  • Manufacturer
  • Service company
  • Supplier / Distributor
Customer segments:
  • Large biotech & big pharma
  • Small biotech
Distribution:
  • Indirect (independent dealer)
Summary Products / Services / Technologies
Number of Biotech Products
Pre-clinical:3
Phase I:7
Phase II:39
Phase III:14
On the market:7
Description of products:
Autogene cevumeran (BNT122/RO7198457)
BNT325/DB-1305
Trastuzumab pamirtecan (BNT323/DB-1303) etc
Technology used:
mRNA-based Platforms
Protein-based Platforms
Cell Therapy-based Platforms
Small Molecule-based Platforms
Financing details
Market cap. / valuation:USD 24'302.64M
Collaborations & Clients
Partnering strategy / collaborations:
Autolus Therapeutics
Bill & Melinda Gates Foundation
Biotheus
Coalition for Epidemic Preparedness Innovations (CEPI)
Crescendo Biologics
Duality Biologics
Fosun Pharma, etc.
© 2026 Biotechgate by Venture Valuation
X